Population Pharmacokinetics of Escalating Doses of Caspofungin in a Phase II Study of Patients with Invasive Aspergillosis

Caspofungin (CAS) is approved for second-line management of proven or probable invasive aspergillosis at a dose of 50 mg once daily (QD). Preclinical and limited clinical data support the concept of the dose-dependent antifungal efficacy of CAS with preservation of its favorable safety profile. Litt...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Würthwein, Gudrun, Cornely, Oliver A., Trame, Mirjam N., Vehreschild, Janne J., Vehreschild, Maria J. G. T., Farowski, Fedja, Müller, Carsten, Boos, Joachim, Hempel, Georg, Hallek, Michael, Groll, Andreas H.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2013
Assuntos:
Pharmacology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3623320/
https://ncbi.nlm.nih.gov/pubmed/23335740
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.01912-12
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados